» Articles » PMID: 27974212

Clonal Variation in Drug and Radiation Response Among Glioma-Initiating Cells Is Linked to Proneural-Mesenchymal Transition

Abstract

Intratumoral heterogeneity is a hallmark of glioblastoma multiforme and thought to negatively affect treatment efficacy. Here, we establish libraries of glioma-initiating cell (GIC) clones from patient samples and find extensive molecular and phenotypic variability among clones, including a range of responses to radiation and drugs. This widespread variability was observed as a continuum of multitherapy resistance phenotypes linked to a proneural-mesenchymal shift in the transcriptome. Multitherapy resistance was associated with a semi-stable cell state that was characterized by an altered DNA methylation pattern at promoter regions of mesenchymal master regulators and enhancers. The gradient of cell states within the GIC compartment constitutes a distinct form of heterogeneity. Our findings may open an avenue toward the development of new therapeutic rationales designed to reverse resistant cell states.

Citing Articles

Targeting metabolic reprogramming in glioblastoma as a new strategy to overcome therapy resistance.

DAprile S, Denaro S, Gervasi A, Vicario N, Parenti R Front Cell Dev Biol. 2025; 13:1535073.

PMID: 40078366 PMC: 11897528. DOI: 10.3389/fcell.2025.1535073.


The Slovenian translational platform GlioBank for brain tumor research: Identification of molecular signatures of glioblastoma progression.

Novak M, Majc B, Malavolta M, Porcnik A, Mlakar J, Hren M Neurooncol Adv. 2025; 7(1):vdaf015.

PMID: 39963438 PMC: 11831694. DOI: 10.1093/noajnl/vdaf015.


Impact of developmental state, p53 status, and interferon signaling on glioblastoma cell response to radiation and temozolomide treatment.

Berezovsky A, Nuga O, Datta I, Bergman K, Sabedot T, Gurdziel K PLoS One. 2025; 20(2):e0315171.

PMID: 39919036 PMC: 11805374. DOI: 10.1371/journal.pone.0315171.


LDH Isoenzyme and GAA-BSA Nanoparticles: A Novel Therapy Approach for Proneural Subtype Glioblastoma Multiforme.

Yang M, Han X, Li H, Du F, Feng C, Gong A J Cancer. 2025; 16(4):1101-1117.

PMID: 39895794 PMC: 11786042. DOI: 10.7150/jca.98452.


Understanding the Immune System and Biospecimen-Based Response in Glioblastoma: A Practical Guide to Utilizing Signal Redundancy for Biomarker and Immune Signature Discovery.

Jackson L, Erickson A, Camphausen K, Krauze A Curr Oncol. 2025; 32(1).

PMID: 39851932 PMC: 11763554. DOI: 10.3390/curroncol32010016.